Kopran Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹211 Cr +79.2% YoYSee revenue, profit and what management said. You are viewing Q4 FY25.
K

Kopran Ltd

Q4 FY25Pharmaceuticals & Biotechnology

Kopran Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹172Cr
−7.4% YoY
+3.7% QoQ
Net profit
₹10Cr
−48% YoY
−6.9% QoQ
Margin
9.92%
−1.7 pp YoY
−2 pp QoQ

Kopran Ltd Q4 FY25 key numbers

Revenue
Year-on-Year Change in Quarterly Revenue: Decrease of Rs. 1,372 Lakhs (~7.37% decline).

As stated in Kopran Ltd's Q4 FY25 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.

Based on Kopran Ltd's Q4 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹271
Market cap₹1.3K Cr
P/E53.7

The short version

Q4 FY 2024-25 Revenue from Operations: Rs. 17,236 Lakhs. Q4 FY 2024-25 Financials (Page 5):.

From Kopran Ltd's Q4 FY25 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q4 FY 2024-25 Revenue from Operations: Rs. 17,236 Lakhs
  • Q4 FY 2023-24 Revenue from Operations: Rs. 18,608 Lakhs
  • Year-on-Year Change in Quarterly Revenue: Decrease of Rs. 1,372 Lakhs (~7.37% decline)
  • Q4 FY 2024-25 Formulations Revenue: Rs.
  • Q4 FY 2024-25 APIs Revenue: Rs.
  • FY 2024-25 Total Sales/Other Income: Rs. 63,359 Lakhs

2 more points from Kopran Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Kopran Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Focus on capacity expansion is highlighted as a strategic imperative (Page 15).
  • Setting up of an API and R&D facility at Panoli is mentioned as part of growth strategy (Page 15).
  • Emphasis on capacity expansion is aligned with developing high-value/high-volume APIs and intermediates (Page 15).
  • Commitment to compliance with global regulatory standards for all plants is noted but without specific project details (Page 16).

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Kopran Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Kopran Ltd said on order book & pipeline — free account, 30 seconds.

Kopran Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Kopran Ltd Q4 FY25 results — key figures

Kopran Ltd Q4 FY25 reported results vs Q4 FY24, ₹ crore
₹ CrQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue172186-7.4%166+3.7%
Operating profit (EBITDA)1722-21.2%20-13.9%
Operating margin9.92%11.66%-1.7 pp11.94%-2 pp
Profit before tax1425-45.6%14-1.1%
Net profit (PAT)1019-48%10-6.9%
EPS (₹)2.013.86-47.9%2.16-6.9%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹211 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Jubilant Pharmo (Q4 FY25)

    Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…

  • Anuh Pharma (Q4 FY25)

    For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…

  • Themis Medicare (Q4 FY25)

    71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Lincoln Pharmaceuticals (Q4 FY25)

    Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Kopran Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Kopran Ltd Q4 FY25 results?

Q4 FY 2024-25 Revenue from Operations: Rs. 17,236 Lakhs. Q4 FY 2024-25 Financials (Page 5):.

What is Kopran Ltd share price analysis?

Kopran Ltd currently shows a neutral. The stock trades at a P/E of 53.7 with a market cap of ₹1,342 Cr. Investors should review the full earnings analysis for detailed insights.

Is Kopran Ltd planning capital expenditure?

Focus on capacity expansion is highlighted as a strategic imperative (Page 15).

Keep Kopran Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.